FIELD: medicine.
SUBSTANCE: group of inventions relates to protein compositions with low viscosity. A liquid pharmaceutical composition for injection contains from 183 to 215 mg/ml of a monoclonal antibody with molecular weight from 120 to 250 kDa; cimetidine or its pharmaceutically acceptable salt; and a pharmaceutically acceptable solvent; where the liquid pharmaceutical composition, when being in a volume suitable for injection, has absolute viscosity from 1 to 100 cP at 25°C, as measured using a viscometer with a cone and a plane or a microfluid viscometer; and absolute viscosity of the liquid pharmaceutical composition is less than absolute viscosity of the reference composition containing an antibody and a pharmaceutically acceptable solvent and not containing cimetidine or its pharmaceutically acceptable salt; where absolute viscosity is extrapolated viscosity at a zero shear rate. A method for administration to a subject of therapeutically effective amount of an antibody, a method for production of a liquid pharmaceutical composition, and a lyophilized composition are also disclosed.
EFFECT: group of inventions provides for quick and convenient administration by means of subcutaneous or intramuscular injection.
21 cl, 9 dwg, 40 tbl, 28 ex
Title | Year | Author | Number |
---|---|---|---|
LIQUID COMPOSITIONS OF PROTEINS CONTAINING AGENTS FOR VISCOSITY REDUCTION | 2014 |
|
RU2710542C2 |
LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS | 2014 |
|
RU2675824C2 |
CONCENTRATED PROTEIN PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION | 2011 |
|
RU2626512C2 |
ANTIBODY FORMULATIONS | 2012 |
|
RU2665810C2 |
NUTRICEUTICAL OPHTHALMOLOGICAL COMPOSITION FOR TREATMENT OF RETINAL PATHOLOGIES WITH A NEOVASCULAR COMPONENT | 2019 |
|
RU2806096C2 |
HIGHLY CONCENTRATED COMPOSITIONS OF MONOCLONAL ANTIBODIES | 2013 |
|
RU2711089C2 |
PHARMACEUTICAL FORMULATION CONTAINING BEVACIZUMAB | 2021 |
|
RU2819797C1 |
METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
COMPOSITION CONTAINING ANTIBODY | 2010 |
|
RU2609658C2 |
SELECTION OF MEDICATIONS FOR LUNG CANCER THERAPY BY MEANS OF ANTIBODY-BASED MATRICES | 2008 |
|
RU2519647C2 |
Authors
Dates
2022-11-02—Published
2014-09-11—Filed